UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007085
Receipt number R000008310
Scientific Title A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.
Date of disclosure of the study information 2012/01/23
Last modified on 2013/03/10 08:05:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

Acronym

A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

Scientific Title

A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

Scientific Title:Acronym

A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

Region

Japan


Condition

Condition

previously treated advanced non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate a feasibility and survival benefit of low dose docetaxel

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Overall survival time
Feasibility

Key secondary outcomes

Objective response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

15mg/m2 of docetaxel was administrated weekly.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Histologicaly or cytologicaly diagnosed previously treated NSCLC.
Stage-IIIb or IV according to sixth edition of TNM classification at the enrollment.
ECOG PS 0 or 1
(1) WBC>3,000/mm3
(2) neutrophil>1,500/mm3
(3) Hb>8.0 g/dL
(4) platelet>100,000/mm3
(5) total bilirubine<1.5 mg/dL
(6) AST(GOT)<70 IU/L
(7) ALT(GPT)<70 IU/L
(8) serum creatinine<1.5 mg/dL

Key exclusion criteria

1) Patients with active double cancer.
2) Patients with infectious disease.
3) Patients with fever higher than 38 degree.
4) Female under pregnancy or lactation period.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshiki Shimizu

Organization

Kansai Medical University

Division name

1st department of internal medicine

Zip code


Address

Fumizono-cho 10-15, Moriguchi-city, Osaka.

TEL

06-6992-1001

Email



Public contact

Name of contact person

1st name
Middle name
Last name Toshiki Shimizu

Organization

Kansai Medical University

Division name

1st department of internal medicine

Zip code


Address

Fumizono-cho 10-15, Moriguchi-city, Osaka.

TEL

06-6992-1001

Homepage URL


Email

shimizto@takii.kmu.ac.jp


Sponsor or person

Institute

Kansai Medical University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

23-7

Org. issuing International ID_1

The Clinical Research Board of Kansai Medical University Takii Hospital

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

関西医科大学附属滝井病院(大阪府)(Kansai Medical University Takii Hospital(Osaka))


Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 23 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.dovepress.com/articles.php?article_id=9925

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2000 Year 01 Month 01 Day

Date of IRB


Anticipated trial start date

2000 Year 02 Month 01 Day

Last follow-up date

2012 Year 01 Month 01 Day

Date of closure to data entry

2012 Year 01 Month 01 Day

Date trial data considered complete

2012 Year 01 Month 01 Day

Date analysis concluded

2012 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 01 Month 17 Day

Last modified on

2013 Year 03 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008310


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name